Our Products

Metformin SR 500/1000mg tablets

  • Overcomes insulin resistance and has extra pancreatic peripheral action
  • Does not produce hyperglycemia in normal subjects
  • Sustained release action ensures convenience of once daily dose

Glimepiride 1/2mg + Metformin SR 500mg tablets

  • 75% Patients achieved <=7% HbA1c1
  • 40% risk reduction in all cause mortality2
  • Improves insulin sensitivity
  • Achieves PPG goals

Voglibose 0.3mg + Metformin 500mg tablets

  • A 24 weeks study on patients (not controlled with basal insulin treatment) alone or in combination with metformin or SU’s1
  • Addition og Voglibose: 0.7% additional reduction in Hba1c level
  • Very safe
  • Significant reduction in body weight

Also available,VOGVID 0.3

Metoprolol (ER) 25/50mg

  • 2.4% increase in LVEF with Metoprolol1
  • Improvement in cardiac function and exercise tolerance with Metoprolol in heart failure with diabetes2
  • Ensure end organ protection

Telmisartan 40mg + Hydrochlorothiazide 12.5mg tablets

  • Greater BP reduction than telmisartan monotherapy1
  • Doubles the responder rate
  • No significant alteration in K levels
  • Telmisartan lowers risk of hospital admission for MI, stroke or heart failure by 15%

Now Available,Complete Range of TELMIVID

  1. TELMIVID CH
  2. TELMIVID HCT 40
  3. TELMIVID AM
  4. TELMIVID 40

Rosuvastatin 10mg tablets.

  • Competitive inhibitor of HMG-CoA reductase
  • Decrease relative risk of heart attack and stroke
  • JUPITER TRIAL (2008) suggested rosuvastatin may decrease the relative risk of heart attack and stroke in patients without hyperlipidemia but with elevated levels of highly sensitive C-reactive protein.